On another front, semaglutide 2.4 mg is in the process of seeking approval in both the United States and the European Union, offering significant potential for individuals with obesity or overweight and related comorbidities, as evidenced by its substantial efficacy in phase 3 trials [88]
This supplement can help decrease fatigue in the body and mind, and it may also improve mild memory problems like absentmindedness or forgetfulness associated with age
Some patients say semaglutide made them feel more anxious or depressed A review of real-world data from healthcare databases and registries is underway
It can also act as a neurotransmitter and may help support immune function and cellular health
Mounjaro leads in reducing A1C and aiding weight loss, while Ozempic is approved to address heart complications in patients with Type 2 diabetes and cardiovascular issues
This is an area of ongoing research, and the results so far are encouraging